| Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors |
Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experience Toronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that pharmaceutical industry veteran Timothy J. Garnett, M.D. |
newsfilecorp.com |
2025-04-29 11:27:00 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics Stock: Is Cannabis Potential Priced In? |
Cardiol Therapeutics shows promise with its CBD-based heart therapy, but a lack of approved drugs and a narrow pipeline raise red flags for cautious investors. |
zacks.com |
2025-04-22 12:25:37 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis |
Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago. Based on a successful end-of-Phase II meeting with the US FDA and subject to MAVERIC outcomes, Cardiol believes the results from MAVERIC will support a New Drug Application. |
newsfilecorp.com |
2025-04-16 11:27:00 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics Announces Year-End 2024 Update on Operations |
Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patientswith acute myocarditis, with topline data expected in Q2 2025 CardiolRx™ granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis,which includes recurrent pericarditis Cash and cash equivalents of $30.6 million as of December 31, 2024,to fund operations into Q3 2026 Toronto, Ontario--(Newsfile Corp. - April 1, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today its year-end 2024 update on operations following the filing of its audited Financial Statements and Management's Discussion and Analysis for the year ended December 31, 2024. Both are available under the Company's profile on EDGAR at www.sec.gov, on SEDAR+ at sedarplus.ca and on the Company's website at cardiolrx.com. |
newsfilecorp.com |
2025-04-01 11:27:00 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference |
Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will present at the TD Cowen 45th Annual Health Care Conference in Boston, MA, on March 5, 2025, at 11:10 a.m. EST. A replay of the live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/). |
newsfilecorp.com |
2025-03-03 09:27:00 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure |
Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death - key underlying mechanisms in heart failure Toronto, Ontario--(Newsfile Corp. - February 20, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today the publication of research in the Journal of the American College of Cardiology: Basic to Translational Science ("JACBTS"), titled "Cannabidiol Prevents Heart Failure Dysfunction and Remodeling Through Preservation of Mitochondrial Function and Calcium Handling" (www.jacc.org/doi/abs/10.1016/j.jacbts.2024.12.009). This research was conducted by scientists from Tecnológico de Monterrey who, together with researchers from the DeBakey Heart and Vascular Center in Houston, TX, are collaborating with Cardiol on the development of the Company's proprietary subcutaneous ("SubQ") formulation of cannabidiol, CRD-38, to treat heart failure with preserved ejection fraction. |
newsfilecorp.com |
2025-02-20 09:27:00 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference |
Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 4:00 p.m. EST. A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/). |
newsfilecorp.com |
2025-02-04 09:27:00 |
Czytaj oryginał (ang.) |
| 5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era |
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio. |
zacks.com |
2025-01-31 11:05:28 |
Czytaj oryginał (ang.) |
| PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis |
Cardiol Therapeutics President and CEO, David Elsley NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President and CEO, David Elsley, who discusses the company's lead oral drug, CardiolRx™, which is entering a late-stage Phase III clinical trial, MAVERIC, for patients with recurrent pericarditis who are at high risk for recurrence. Cardiol Therapeutics is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. |
globenewswire.com |
2024-12-19 10:30:00 |
Czytaj oryginał (ang.) |
| 3 Penny Stocks Ready to Break Out in 2025 |
Known for their uncommonly pronounced risk/reward profile, penny stocks all too often entice investors with their low prices and potential for significant returns, only to fail to live up to those expectations. The world of penny stocks is also characterized by pump-and-dump and other scams, facilitated by the fact that most penny stock companies do not have an extensive history of financial reporting or an established brand name and presence. |
marketbeat.com |
2024-11-29 10:02:25 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics reports promising Phase II results for recurrent pericarditis therapy |
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced encouraging results from its Phase II MAvERIC-Pilot study, showcasing the sustained efficacy of its anti-inflammatory therapy, CardiolRx, in treating symptomatic recurrent pericarditis. The findings, which were presented at the American Heart Association Scientific Sessions 2024, highlighted marked improvements in pericarditis pain and inflammation, with benefits persisting throughout the 26-week trial. |
proactiveinvestors.com |
2024-11-18 14:36:52 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024 |
Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week study Episodes of pericarditis per year substantially reduced MAvERIC-Pilot results support advancing CardiolRx™ into the Phase II/III MAVERIC-2and the Phase III MAVERIC-3 clinical trials Toronto, Ontario--(Newsfile Corp. - November 18, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today reported clinical results from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis. The data showed that the marked improvements in both pericarditis pain and inflammation, previously reported at the 8-week primary endpoint, were maintained throughout the extension period of the 26-week study. |
newsfilecorp.com |
2024-11-18 13:37:00 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index |
NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of market insights and company news, proudly announces that Cardiol Therapeutics Inc. (NASDAQ: CRDL, TSX: CRDL) has been added to the PRISM Emerging Biotech Index, which spotlights companies leading innovation and creating market impact within the biotech sector. Cardiol's focus on anti-inflammatory and anti-fibrotic therapies for heart disease, including its lead candidate CardiolRx™, positions it as a pioneer in addressing major unmet needs in cardiac care. |
globenewswire.com |
2024-11-13 10:00:00 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index |
Company advancing late-stage clinical programs with novel therapies that target underserved heart diseases NEW YORK, November 13, 2024 – PRISM MediaWire – PRISM MarketView, a leading provider of market insights and company news, proudly announces that Cardiol Therapeutics Inc. |
prismmediawire.com |
2024-11-13 09:59:40 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis |
MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with the Company's planned Phase III program. Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced plans to expand the MAVERIC clinical development program and advance CardiolRx™ into a late-stage clinical trial ("MAVERIC-2") to evaluate the impact of CardiolRx™ in recurrent pericarditis patients following cessation of interleukin-1 ("IL-1") blocker therapy. |
newsfilecorp.com |
2024-10-22 10:30:00 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics raises $15.5M following over-allotment option exercise |
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) has successfully raised a total of US$15.5 million through a public offering. The company announced that Canaccord Genuity (TSX:CF, LSE:CF) has exercised its over-allotment option in full, purchasing an additional 1,265,625 Class A common shares at $1.60 per share. |
proactiveinvestors.com |
2024-10-11 13:35:55 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option |
Oakville, Ontario--(Newsfile Corp. - October 11, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that, further to its successfully completed public offering of an aggregate of 8,437,500 Class A common shares of the Company (the "Common Shares") at a price to the public of US$1.60 per Common Share (the "Offering Price") for gross proceeds of US$13.5 million (the "Offering"), Canaccord Genuity has purchased an additional 1,265,625 Common Shares at the Offering Price pursuant to their exercise in full of the over-allotment option (the "Over-Allotment Option"), for additional gross proceeds to the Company of $2,025,000 before deducting the underwriting commissions. After giving effect to the full exercise of the Over-Allotment Option, Cardiol sold 9,703,125 Common Shares under the Offering, for aggregate gross proceeds of US$15,525,000. |
newsfilecorp.com |
2024-10-11 12:39:00 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares |
Oakville, Ontario--(Newsfile Corp. - October 10, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, confirmed today that it has successfully closed its previously announced public offering (the "Offering") of 8,437,500 Class A common shares of the Company (the "Common Shares") at a price to the public of US$1.60 per Common Share for gross proceeds of US$13.5 million, before deducting the underwriting discounts and commissions and estimated expenses incurred in connection with the Offering. As previously stated, the Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis and for general and administrative expenses, working capital and other expenses. |
newsfilecorp.com |
2024-10-10 13:09:00 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics prices $13.5M public offering |
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL), a clinical-stage life sciences company focused on heart disease treatments, announced on Wednesday it is raising US$13.5 million through a public offering of 8,437,500 Class A common shares priced at $1.60 per share. The company said it plans to use the net proceeds from the offering to advance the clinical development of its lead product, CardiolRx, for the treatment of recurrent pericarditis, a condition involving inflammation of the heart's outer lining. |
proactiveinvestors.com |
2024-10-09 13:13:02 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares |
Oakville, Ontario--(Newsfile Corp. - October 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today the pricing of its previously announced public offering (the "Offering") of 8,437,500 Class A common shares of the Company (the "Common Shares") at a price to the public of US$1.60 per Common Share for gross proceeds of US$13.5 million before deducting the underwriting discounts and commissions and estimated expenses incurred in connection with the Offering. The Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis and for general and administrative expenses, working capital and other expenses. |
newsfilecorp.com |
2024-10-09 11:58:00 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares |
Toronto, Ontario--(Newsfile Corp. - October 8, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce the Company has filed a preliminary prospectus supplement (the "Supplement") to its short form base shelf prospectus dated July 12, 2024 (the "Base Prospectus") in connection with a proposed public offering (the "Offering") of Class A common shares (the "Common Shares"). The Supplement was also filed with the U.S. Securities Exchange and Commission (the "SEC"), as part of a registration statement on Form-10, as amended, which was declared effective by the SEC on July 16, 2024, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States. |
newsfilecorp.com |
2024-10-08 20:01:00 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics reaches target enrollment for Phase II acute myocarditis trial |
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced that it has reached its target enrollment of 100 patients in the ARCHER trial, a Phase II randomized, double-blind, placebo-controlled study evaluating CardiolRx for myocardial recovery in patients with acute myocarditis. "We are pleased to have achieved our target patient enrollment in the ARCHER trial, which reflects the commitment and dedication of our clinical collaborators and participating patients," said Andrew Hamer, chief medical officer at Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL). |
proactiveinvestors.com |
2024-09-24 13:12:55 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis |
Toronto, Ontario--(Newsfile Corp. - September 24, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced it has achieved the target patient enrollment of 100 patients in "ARCHER", its Phase II randomized, double-blind, placebo-controlled trial evaluating the impact of CardiolRx™ on myocardial recovery in patients with acute myocarditis. "We are pleased to have achieved our target patient enrollment in the ARCHER trial, which reflects the commitment and dedication of our clinical collaborators and participating patients. |
newsfilecorp.com |
2024-09-24 11:27:00 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics to unveil data from Phase 2 recurrent pericarditis study |
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced that it has completed its Phase 2 MAvERIC-Pilot study investigating the impact of its novel therapy CardiolRx in patients with recurrent pericarditis and it will be presenting the results at American Heart Association Scientific Sessions 2024. The company said full clinical data from the trial will be reported during an oral presentation at the event on Monday, November 18, 2024, starting at 9:45am. |
proactiveinvestors.com |
2024-09-10 14:02:06 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024 |
Full clinical data will be reported in an oral presentation at the premier global event for advancements in cardiovascular science and medicine on November 18, 2024 Toronto, Ontario--(Newsfile Corp. - September 10, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced the data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis will be reported in an oral presentation as part of the Laennec Clinician-Educator Award & Lecture that runs from 9:45 a.m. to 11:00 a.m. |
newsfilecorp.com |
2024-09-10 11:27:00 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders |
Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its annual general and special meeting of shareholders (the "Meeting") held virtually via live audio webcast, on June 26, 2024. Shareholders voted in favour of all management resolutions proposed in the Company's management information circular dated May 13, 2024. |
newsfilecorp.com |
2024-06-27 16:29:00 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT |
Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company's virtual Annual General and Special Meeting of Shareholders (the "AGM") will be webcast on June 26, 2024, at 4:30 p.m. EDT. Cardiol Therapeutics 2024 AGM When: June 26, 2024, at 4:30 p.m. |
newsfilecorp.com |
2024-06-25 11:27:00 |
Czytaj oryginał (ang.) |
| Cardiol Therapeutics releases Phase II data showing CardiolRx reduces pericarditis pain and inflammation |
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) released data from its Phase II MAvERIC-Pilot study demonstrating that its lead drug candidate CardiolRx significantly reduces pericarditis pain and inflammation, showing promise as a non-immunosuppressive treatment option. The study, which assessed the efficacy of CardiolRx in treating symptomatic recurrent pericarditis, revealed a significant reduction in patient-reported pericarditis pain, the primary efficacy endpoint. |
proactiveinvestors.com |
2024-06-13 16:10:21 |
Czytaj oryginał (ang.) |